In a recent small study, Yoshimine et al. [5] observed that patients with more favorable prognoses exhibited non-adenocarcinoma histotypes, a high frequency of EGFR mutations, and were more likely to receive immune checkpoint inhibitor (ICI) therapy. This evidence concerns the gene EGFR and adenocarcinoma.